Durable Response to Ivosidenib in Post-transplant Relapse and Leukemic Transformation of Myelodysplastic Syndrome with New Complex Karyotype and R132C Mutation
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
Citing Articles
Alkhaldi H, Kharfan-Dabaja M, El Fakih R, Aljurf M Bone Marrow Transplant. 2023; 58(10):1075-1083.
PMID: 37516808 DOI: 10.1038/s41409-023-02073-6.
References
1.
Mossner M, Jann J, Wittig J, Nolte F, Fey S, Nowak V
. Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure. Blood. 2016; 128(9):1246-59.
DOI: 10.1182/blood-2015-11-679167.
View
2.
Cazzola M
. Myelodysplastic Syndromes. N Engl J Med. 2020; 383(14):1358-1374.
DOI: 10.1056/NEJMra1904794.
View
3.
Quek L, Ferguson P, Metzner M, Ahmed I, Kennedy A, Garnett C
. Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia. Blood Adv. 2018; 1(3):193-204.
PMC: 5737177.
DOI: 10.1182/bloodadvances.2016000760.
View
4.
Jacoby M, Duncavage E, Chang G, Miller C, Shao J, Elliott K
. Subclones dominate at MDS progression following allogeneic hematopoietic cell transplant. JCI Insight. 2018; 3(5).
PMC: 5922277.
DOI: 10.1172/jci.insight.98962.
View
5.
Stein E, DiNardo C, Fathi A, Pollyea D, Stone R, Altman J
. Molecular remission and response patterns in patients with mutant- acute myeloid leukemia treated with enasidenib. Blood. 2018; 133(7):676-687.
PMC: 6384189.
DOI: 10.1182/blood-2018-08-869008.
View